Clinical characteristics and prognosis of temporary miller fisher syndrome following COVID-19 vaccination: a systematic review of case studies
Клинические характеристики и прогноз транзиторного синдрома Миллера—Фишера после вакцинации против COVID-19: систематический обзор клинических случаев
2023-09-21
SCID: 54.1/5ye5ah53
Discuss with AI
COVID-19 vaccinationGuillain-Barré syndromeMiller Fisher syndromeintravenous immunoglobulinsystematic review
Figures from the paper
Abstract (AI)
BACKGROUND: Miller Fisher syndrome (MFS) is a subtype of Guillain-Barré syndrome (GBS) which is characterized by the three components of ophthalmoplegia, ataxia, and areflexia. Some studies reported MFS as an adverse effect of the COVID-19 vaccination. We aimed to have a detailed evaluation on demographic, clinical, and para-clinical characteristics of subjects with MFS after receiving COVID-19 vaccines. MATERIALS AND METHODS: A thorough search strategy was designed, and PubMed, Web of Science, and Embase were searched to find relevant articles. Each screening step was done by twice, and in case of disagreement, another author was consulted. Data on different characteristics of the patients and types of the vaccines were extracted. The risk of bias of the studies was assessed using Joanna Briggs Institute (JBI) tools. RESULTS: In this study, 15 patients were identified from 15 case studies. The median age of the patients was 64, ranging from 24 to 84 years. Ten patients (66.6%) were men and Pfizer made up 46.7% of the injected vaccines. The median time from vaccination to symptoms onset was 14 days and varied from 7 to 35 days. Furthermore,14 patients had ocular signs, and 78.3% (11/14) of ocular manifestations were bilateral. Among neurological conditions, other than MFS triad, facial weakness or facial nerve palsy was the most frequently reported side effect that was in seven (46.7%) subjects. Intravenous immunoglobulin (IVIg) was the most frequently used treatment (13/15, 86.7%). Six patients received 0.4 g/kg and the four had 2 g/kg. Patients stayed at the hospital from five to 51 days. No fatal outcomes were reported. Finally, 40.0% (4/15) of patients completely recovered, and the rest experienced improvement. CONCLUSION: MFS after COVID-19 immunization has favorable outcomes and good prognosis. However, long interval from disease presentation to treatment in some studies indicates that more attention should be paid to MFS as the adverse effect of the vaccination. Due to the challenging diagnosis, MFS must be considered in list of the differential diagnosis in patients with a history of recent COVID-19 vaccination and any of the ocular complaints, ataxia, or loss of reflexes, specially for male patients in their 60s and 70s.
Key Findings
1
A systematic review identified 15 reported patients with Miller Fisher syndrome (MFS) following COVID-19 vaccination, with a median age of 64 years and 66.6% being men.
2
Intravenous immunoglobulin was the most commonly reported treatment, administered to 13 of 15 patients (86.7%), with reported doses of 0.4 g/kg or 2 g/kg.
3
Ocular manifestations occurred in 14 patients, and 78.3% of these ocular signs were bilateral; facial weakness or facial nerve palsy was the most frequent additional neurological finding.
4
Outcomes were favorable: no deaths occurred, 40.0% of patients completely recovered, and the remaining patients improved; delayed treatment in some reports highlights the need for earlier recognition.
5
Symptoms began a median of 14 days after vaccination, with onset ranging from 7 to 35 days; Pfizer vaccines accounted for 46.7% of reported cases.
Research Object
Miller Fisher syndrome occurring after COVID-19 vaccination
Research Subject
Demographic, clinical, paraclinical characteristics, treatment, and prognosis of post-vaccination Miller Fisher syndrome
Publication Details
Publication Date
2023-09-21
Journal
Publisher
ISSN
Cited by
6
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest